Tivey, Ann http://orcid.org/0000-0002-5389-3741
Church, Matt http://orcid.org/0000-0002-5825-3241
Rothwell, Dominic
Dive, Caroline
Cook, Natalie http://orcid.org/0000-0003-2606-1082
Article History
Accepted: 17 June 2022
First Online: 1 August 2022
Change Date: 16 December 2022
Change Type: Update
Change Details: In the version of this article initially published, the peer reviewer name Y. Nakamura was misspelled and is now amended in the HTML and PDF versions of the article.
Competing interests
: C.D. has acted as a consultant and/or adviser of AstraZeneca, Boehringer Ingelheim, Biocartis, GRAIL and Merck, and has received research funding from Angle, Amgen, Astex Pharmaceuticals, AstraZeneca, Bayer, Bioven, Bristol Myers Squibb, Boehringer Ingelheim, Carrick Therapeutics, Celgene, Clearbridge Biomedics, Epigene Therapeutics, GlaxoSmithKline, Menarini, Merck AG, Neomed Therapeutics, Novartis, Roche, Taiho Oncology and Thermo Fisher Scientific. N.C. has received research funding from AstraZeneca, Avacta, Bayer, Boehringer, Eisai, Merck, Orion, Pfizer, RedX, Roche, Starpharma, Stemline Tarveda, Taiho Oncology and UCB. The other authors declare no competing interests.
Free to read: This content has been made available to all.